MedTrace Logo

Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants

NCT04104828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2022-03-23

No results posted yet for this study

Summary

The primary objective of the pilot study is to compare inflammatory responses in blood sera from patients receiving first allergen immunotherapy (AIT) with aluminium (Alum), microcrystalline tyrosine (MCT), or a combination of MCT and monophosphoryl lipid A (MPLA) as adjuvants. The AIT products are containing allergen extracts of grass and tree pollen). Blood is collected before as wells as one day, seven days, and 6-7 weeks after first AIT, and the blood is analysed for content of inflammatory proteins and antibodies.

Conditions

  • Allergic Rhinitis

Interventions

BIOLOGICAL

Allergovit

Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis

BIOLOGICAL

Polvac

Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis

BIOLOGICAL

Pollinex Quattro

Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis

Sponsors & Collaborators

  • Zentrums für Rhinologie und Allergologie Wiesbaden

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Pål Johansen, Prof., PhD · University Hospital Zürich & Unversity of Zurich

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-05
Primary Completion
2021-03-31
Completion
2021-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04104828 on ClinicalTrials.gov